ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

axatilimab

Also written as “Axatilimab”, “INCA034176” and “SNDX-6352”.

Its studies are mostly in Bronchiolitis Obliterans Syndrome · Idiopathic Pulmonary Fibrosis · Neoplasm Metastasis · Coronavirus Infections, led by 2 companies.

Drug pageAxatilimab: every studyAll 26 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Feb 9, 202412 company-led studies, 7 open or runningNext primary completion: Jan 6, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Incyte76 open or runningphase 3since Feb 9, 2024Feb 9, 2024Jan 6, 2027phase 2 · NCT06843408
Syndax Pharmaceuticalsits history only51 open or runningphase 2since Jul 10, 2018Jun 30, 2017none ahead

Also a collaborator on its studies: DevPro Biopharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Incyte only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2019Named axatilimabINNProposed as its International Nonproprietary Name in WHO's List 121 · before, INCA034176, SNDX-6352
  2. Feb 9, 2024First study: phase 3 study in Bronchiolitis Obliterans SyndromeFirst studyNCT06263478 · 21 enrolled · Japan
  3. Apr 25, 2024Phase 2 study in Bronchiolitis Obliterans SyndromeNCT06388564 · 130 enrolled · United States, Belgium, Canada and more
  4. Aug 30, 2024Phase 3 study in Bronchiolitis Obliterans SyndromeNCT06585774 · 240 planned · United States, Australia, Austria and more
  5. Nov 27, 2024Phase 1 study in Healthy ParticipantsNCT06713590 · 72 enrolled · United States
  6. Feb 6, 2025Phase 3 study in Bronchiolitis Obliterans SyndromeNCT06821542 · 9 enrolled · Austria, Belgium, Czechia and more
  7. Feb 20, 2025Phase 2 study in Bronchiolitis Obliterans SyndromeNCT06843408 · 32 enrolled · China
  8. Aug 8, 2025Phase 2 study in Bronchiolitis Obliterans SyndromeNCT07124078 · 60 planned · United States, Belgium, Germany and more

Ahead

  1. Jan 6, 2027Primary completion: phase 2 study in Bronchiolitis Obliterans SyndromeNCT06843408
  2. Sep 28, 2027Primary completion: phase 3 study in Bronchiolitis Obliterans SyndromeNCT06585774
  3. May 31, 2028Primary completion: phase 3 study in Bronchiolitis Obliterans SyndromeNCT06821542
  4. Jan 31, 2029Primary completion: phase 2 study in Bronchiolitis Obliterans SyndromeNCT07124078

TargetBeta

CSF1R →read by rule
“A humanized immunoglobulin (Ig) G4 monoclonal antibody directed against colony-stimulating factor 1 receptor (CSF-1R; CSF1R; macrophage-CSFR; M-CSFR; CD115; c-fms), ”NCIt, by rule
“Macrophage colony stimulating factor receptor inhibitor”ChEMBL 37, by rule

Other programs on CSF1R

ProgramCompanyFurthest phaseStudies
quizartinibruleDaiichi Sankyophase 322
pimicotinibruleAbbisko Caymanphase 314
vimseltinibruleOno Pharmaceuticalphase 38
seralutinibrulegb002-inc-a-wholly-owned-subsidiary-of-gossamer-bio-incphase 38
adrixetinibrulequrient-co-ltdphase 23

Studies

All 7 Incyte leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07124078Bronchiolitis Obliterans Syndrome · United States, Belgium, Germany and more2RecruitingJan 31, 202960
NCT06843408Bronchiolitis Obliterans Syndrome · China2Active, not recruitingJan 6, 202732
NCT06821542Bronchiolitis Obliterans Syndrome · Austria, Belgium, Czechia and more3Active, not recruitingMay 31, 20289
NCT06713590Healthy Participants · United States1CompletedJun 6, 202572
NCT06585774Bronchiolitis Obliterans Syndrome · United States, Australia, Austria and more3RecruitingSep 28, 2027240
NCT06388564Bronchiolitis Obliterans Syndrome · United States, Belgium, Canada and more2Active, not recruitingOct 1, 2026130
NCT06263478Bronchiolitis Obliterans Syndrome · Japan3Active, not recruitingAug 6, 202521

How it is read

Names in the registry

  • “Axatilimab”, 5 entries
  • “INCA034176”, 5 entries
  • “axatilimab”, 1 entry
  • “SNDX-6352”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.